Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pelletier-Fleury, N.
Right arrow Articles by Fardeau, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pelletier-Fleury, N.
Right arrow Articles by Fardeau, M.
(Chest. 1996;110:411-416.)
© 1996 American College of Chest Physicians

The Cost of Treating COPD Patients With Long-term Oxygen Therapy in a French Population

Nathalie Pelletier-Fleury MD1; Jean-Louis Lanoe PhD1; Bernard Fleury MD2; and Michéle Fardeau PhD1

1 From the Centre de recherches en Economie de la Santé, INSERM U357, CHU de Kremlin-Bicêtre, pavillon de la Force, Kremlin-Bicêtre, France
2 From the Unite de Pneumologie, CHU Saint Antoine, Paris, France

Objective: In greater Paris and its surroundings (as it is in all France), oxygen is home delivered by not-for-profit (NP) associations or profit-making (PM) health organizations. Both are financed by the national health insurance. This dual context and the current economic climate justify an economic evaluation of all respiratory care for patients with COPD receiving long-term oxygen therapy (LTO). This pragmatic approach identifies the variables that have the greatest impact on direct medical costs and estimates the annual cost for respiratory care per COPD patient.

Design: Retrospective study.

Setting: Health insurance scheme for self-employed professionals (CANAM).

Patients and methods: Between July 1985 and March 1994, 234 patients registered in CANAM files began LTO, 24% in the PM sector, 76% in the NP sector, mainly using concentrator (78%), mean age of 74±10years, male predominance (74%), PaO2 of 56.2±10.5 mm Hg, FEV1/FVC of 43±15%, and 51% having 1 or more severe illness(es) associated. The economic appraisal was performed on a representative sample of 61 patients and measured the total resources consumption for respiratory care per COPD patient and per year (physician visits and tests, drugs, physiotherapy, oxygen therapy, hospitalizations for acute respiratory failure, transport costs).

Results: A quarter of the patients in each sector did not meet the LTO prescription guidelines (PaO2 >60 mm Hg). For patients having their oxygen delivered by NP sector, the total ambulatory cost for respiratory care was lower ($4,506 per patient and per year vs $5,399) because they mainly used concentrator, all the other direct ambulatory costs being equal. The total annual cost for respiratory care of a COPD patient receiving LTO amounted to $11,672 (NP and PM sectors merged). Oxygen therapy represented 73% of the total ambulatory cost. In a multiple linear regression model, hospitalization represented the largest share of cost, significantly higher when PaO2 was 55 mm Hg or less ($2,287 per patient per year vs $8,717). In contrast, none of the covariates (age, sex, PaO2, FEV1/FVC) influenced at a significant level the total cost of visits, tests, drugs, and physiotherapy, amounting to $1,507.

Conclusion: As oxygen treatment plays an important role in the variation of costs, further pragmatic studies should help to better understand what are the real motivations to choose one mode of oxygen administration more than another and should determine factors that may lead physicians sometimes not to comply with clinical guidelines.

Key Words: COPD • domiciliary oxygen therapy • economic evaluation

Submitted on October 27, 1995
Accepted on March 6, 1996




This article has been cited by other articles:


Home page
ChestHome page
R. A. Incalzi, A. Corsonello, C. Pedone, F. Corica, P. Carbonin, R. Bernabei, and on Behalf of the GIFA Investigators
Construct Validity of Activities of Daily Living Scale: A Clue To Distinguish the Disabling Effects of COPD and Congestive Heart Failure
Chest, March 1, 2005; 127(3): 830 - 838.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
C. A. Sant'Anna, R. Stelmach, M. I. Zanetti Feltrin, W. J. Filho, T. Chiba, and A. Cukier
Evaluation of Health-Related Quality of Life in Low-Income Patients With COPD Receiving Long-term Oxygen Therapy
Chest, January 1, 2003; 123(1): 136 - 141.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
J. C. Chaney, K. Jones, K. Grathwohl, and K. N. Olivier
Implementation of an Oxygen Therapy Clinic to Manage Users of Long-term Oxygen Therapy
Chest, November 1, 2002; 122(5): 1661 - 1667.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
C. Casanova, B. R. Celli, L. Tost, E. Soriano, J. Abreu, V. Velasco, and F. Santolaria
Long-term Controlled Trial of Nocturnal Nasal Positive Pressure Ventilation in Patients With Severe COPD
Chest, December 1, 2000; 118(6): 1582 - 1590.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
G. H. Guyatt, D. A. McKim, P. Austin, R. Bryan, J. Norgren, B. Weaver, and R. S. Goldstein
Appropriateness of Domiciliary Oxygen Delivery
Chest, November 1, 2000; 118(5): 1303 - 1308.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
S. D. Sullivan, S. D. Ramsey, and T. A. Lee
The Economic Burden of COPD
Chest, February 1, 2000; 117(2_suppl): 5S - 9S.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1996 by the American College of Chest Physicians.